All Updates

All Updates

icon
Filter
Partnerships
Better Therapeutics enters rebate agreement with major pharmacy benefit manager for AspyreRx diabetes treatment
Preventive Healthcare
Feb 6, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
Preventive Healthcare

Preventive Healthcare

Feb 6, 2024

Better Therapeutics enters rebate agreement with major pharmacy benefit manager for AspyreRx diabetes treatment

Partnerships

  • Better Therapeutics, a prescription digital therapeutic startup, has entered a rebate agreement with a major pharmacy benefit manager (PBM) regarding its AspyreRx product.

  • Under this agreement, the PBM's plan participants gain access to add AspyreRx to their formularies with rebate eligibility. AspyreRx, approved by the FDA in July 2023 to treat adults with type 2 diabetes, is designed to change neural pathways, causing lasting behavioral change and addressing the underlying causes of the disease. Better Therapeutics is actively promoting its PDTs to health plans, PBMs, and Group Purchasing Organizations to increase accessibility and coverage. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.